John E Bennett

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    J Antimicrob Chemother 63:i23-6. 2009
  2. ncbi request reprint Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S113-6. 2003
  3. ncbi request reprint Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S117-22. 2003
  4. ncbi request reprint Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S123-7. 2003
  5. ncbi request reprint Salvage therapy for aspergillosis
    John E Bennett
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Clin Infect Dis 41:S387-8. 2005
  6. ncbi request reprint The debate: a case for randomized controls in invasive aspergillosis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Med Mycol 44:S305-8. 2006
  7. pmc Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 48:1773-7. 2004
  8. pmc STB5 is a negative regulator of azole resistance in Candida glabrata
    Jason A Noble
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 57:959-67. 2013
  9. pmc Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates
    Huei Fung Tsai
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 54:3308-17. 2010
  10. pmc Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants
    Huei Fung Tsai
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 50:1384-92. 2006

Collaborators

Detail Information

Publications32

  1. pmc The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    J Antimicrob Chemother 63:i23-6. 2009
    ....
  2. ncbi request reprint Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S113-6. 2003
    ..An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice...
  3. ncbi request reprint Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S117-22. 2003
    ....
  4. ncbi request reprint Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S123-7. 2003
    ....
  5. ncbi request reprint Salvage therapy for aspergillosis
    John E Bennett
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Clin Infect Dis 41:S387-8. 2005
    ..e., the design allows the comparison of comparable items), entry criteria (in particular, the duration of therapy before salvage therapy is introduced), and outcome criteria that determine whether or not the treatment was successful...
  6. ncbi request reprint The debate: a case for randomized controls in invasive aspergillosis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Med Mycol 44:S305-8. 2006
    ..In an era of increasing cost containment, it will be the randomized trials that provide the clinician with the information needed to avoid inappropriate use of expensive drugs and drug combinations...
  7. pmc Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 48:1773-7. 2004
    ..The rapidity and regularity of the rising resistance indicated that C. glabrata is able to upregulate drug efflux without losing the ability to maintain colonization...
  8. pmc STB5 is a negative regulator of azole resistance in Candida glabrata
    Jason A Noble
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 57:959-67. 2013
    ..Expression analysis found that CgSTB5 shares many transcriptional targets with CgPDR1 but, unlike the latter, is a negative regulator of pleiotropic drug resistance, including the ABC transporter genes CDR1, PDH1, and YOR1...
  9. pmc Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates
    Huei Fung Tsai
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 54:3308-17. 2010
    ..In summary, gain-of-function mutations in CgPDR1 contributed to the clinical azole resistance, but different mutations had various degrees of impact on the CgPDR1 target genes...
  10. pmc Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants
    Huei Fung Tsai
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 50:1384-92. 2006
    ..Thus, CgPDR1 encodes a transcriptional regulator of a pleiotropic drug resistance network and contributes to the azole resistance of clinical isolates and petite mutants...
  11. pmc Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension
    Huei Fung Tsai
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Clinical Center NIH, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 48:2483-9. 2004
    ..2% cholesterol. Exogenous sterols also restored growth under conditions of low oxygen tension. Finally, complementation of the Cgerg1 mutation restored the levels of [(3)H]fluconazole uptake and drug susceptibility to wild-type levels...
  12. ncbi request reprint The bZip transcription factor Cgap1p is involved in multidrug resistance and required for activation of multidrug transporter gene CgFLR1 in Candida glabrata
    Kuang Hua Chen
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
    Gene 386:63-72. 2007
    ..Taken together, this report demonstrated that CgAP1 plays a critical role in response to various stresses in C. glabrata and reduces the stress through transcriptional activation of its target genes including CgFLR1...
  13. pmc Transcriptional profiling of Candida glabrata during phagocytosis by neutrophils and in the infected mouse spleen
    Yuichi Fukuda
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 81:1325-33. 2013
    ..These results are consistent with reported results of other fungi responding to phagocytosis, indicating that a rapid shift in metabolism is required for growth in a carbohydrate-limited intracellular environment...
  14. ncbi request reprint Function of Candida glabrata ABC transporter gene, PDH1
    Koichi Izumikawa
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Yeast 20:249-61. 2003
    ..Abundance of PDH1 and CgCDR1 mRNA in C. glabrata was increased by rhodamine 6G, cycloheximide and oligomycin, properties in common with PDR5. PDH1, CgCDR1 and PDR5 have striking similarities in function and regulation...
  15. ncbi request reprint Echinocandins for candidemia in adults without neutropenia
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 355:1154-9. 2006
  16. doi request reprint Update on azole antifungals
    Dimitrios I Zonios
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Semin Respir Crit Care Med 29:198-210. 2008
    ..Multiple daily dosing, a need for fatty foods for absorption, and absence of an intravenous formulation restrict its use to selected populations...
  17. pmc Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment
    Qingdi Quentin Li
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Mol Biol 13:22. 2012
    ..The present study aimed to identify reference genes as internal controls for gene expression studies by RT-qPCR in azole-stimulated Candida glabrata...
  18. pmc Hallucinations during voriconazole therapy
    Dimitrios I Zonios
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 47:e7-e10. 2008
    ..Hallucinations associated with voriconazole use are not uncommon. Doctors should be aware of this complication, and the recipients of the drug should be reassured that the hallucinations are an effect of the drug...
  19. pmc Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors
    Dimitrios I Zonios
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:287-94. 2008
    ..CD8 T lymphocytopenia (< 180/mm(3)) and the degree of CD4 T cell activation (measured by HLA-DR expression) at presentation were associated with adverse outcome (opportunistic infection-related death; P = .003 and .02, respectively)...
  20. ncbi request reprint Kre29p is a novel nuclear protein involved in DNA repair and mitotic fidelity in Candida glabrata
    Taiga Miyazaki
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Genet 50:11-22. 2006
    ..These results suggest the involvement of C. glabrata Kre29p in DNA repair. To our knowledge, this is the first report addressing a cellular protein involved in DNA repair in C. glabrata...
  21. pmc Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice
    Justina Y Ju
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 46:1240-5. 2002
    ..This murine model provided evidence of the efficacy of amphotericin B and caspofungin but not of fluconazole against C. glabrata infection...
  22. pmc Disseminated microsporidiosis in an immunosuppressed patient
    Eric G Meissner
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Emerg Infect Dis 18:1155-8. 2012
    ..The causative organism was identified as Tubulinosema acridophagus, confirming this genus of microsporidia as a novel human pathogen...
  23. ncbi request reprint Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients
    Karoll J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:967-72. 2003
    ..Q-PCR was more sensitive than the antigenemia test and had sufficient specificity for clinical use...
  24. ncbi request reprint Cryptococcosis and idiopathic CD4 lymphocytopenia
    Dimitrios I Zonios
    Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Medicine (Baltimore) 86:78-92. 2007
    ..Patients with cryptococcal infection and ICL have an increased likelihood of developing dermatomal zoster. The long-term follow-up of these patients offers some reassurance regarding favorable prognosis...
  25. pmc Hematogenously disseminated skin disease caused by Mucor velutinosus in a patient with acute myeloid leukemia
    Janyce A Sugui
    Molecular Microbiology Section, Laboratory of Clinical Infectious Diseases, National Institutes ofHealth, Bethesda, Maryland 20817 1811, USA
    J Clin Microbiol 49:2728-32. 2011
    ..We believe this to be the first published report of a clinical case of mucormycosis due to M. velutinosus, as well as a rare case of dissemination from a deep site to skin...
  26. ncbi request reprint Successful treatment of coccidioidal meningitis with voriconazole
    Karoll J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1882, USA
    Clin Infect Dis 36:1619-22. 2003
    ..The patient had photosensitivity after 10 weeks of treatment, but this improved when the voriconazole dose was lowered. Continuous voriconazole therapy kept coccidioidal meningitis in complete remission in this patient for >2 years...
  27. pmc A cluster of cases of nosocomial legionnaires disease linked to a contaminated hospital decorative water fountain
    Tara N Palmore
    Warren Grant Magnusen Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1888, USA
    Infect Control Hosp Epidemiol 30:764-8. 2009
    ..We report the investigation of a cluster of cases of nosocomial pneumonia attributable to Legionella pneumophila serogroup 1 that occurred among patients on our stem cell transplantation unit...
  28. pmc Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance
    Taiga Miyazaki
    Second Department of Internal Medicine, Nagasaki University School of Medicine, 1 7 1 Sakamoto, Nagasaki 852 8501, Japan
    Antimicrob Agents Chemother 50:580-6. 2006
    ..The finding questions the clinical significance of this resistance mechanism...
  29. ncbi request reprint Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome
    Thomas F Patterson
    Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Clin Infect Dis 41:1448-52. 2005
    ..In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis...
  30. ncbi request reprint Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign
    Reginald E Greene
    Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 44:373-9. 2007
    ....
  31. ncbi request reprint Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    ..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
  32. pmc Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C
    Ben de Pauw
    Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 46:1813-21. 2008
    ..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...